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SUMMARY
The synthesis of 5-(4-fluoro-phenyl)-3-(8-hydroxy-
quinolin-5-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrim-
idine-6-carbonitrile 4 was achieved by one-pot 
three-component synthesis using p-TSA (10 mol %) 
in refluxing CH3CN. Compound 4 was utilized to 
synthesize  a new series of  thiazolo[3,2-a]pyrimidines 
6-8, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles 10, 11a-c 
and 12a-c. Also, derivatives of Schiff bases 13a-c of 
compound 9 were obtained by the treatment with 
some aromatic aldehydes. The latter compounds un-
derwent Mannich reaction with morpholin to afford 
the N-morpholinomethyl- amino derivatives 14a-c. 
The structures of the new compounds are supported 
by FT IR, 1H NMR, 13 CNMR, Mass spectroscopy and 
elemental analysis. All newly synthesized compounds 
were screened for their antimicrobial activity.
Keywords: One-pot reaction, thiazolo[3,2-a]pyrim-
idines, triazoles, triazolo[3,4-b] thiadiazoles, antimi-
crobial activity. 
RESUMEN
La síntesis del 5-(4-flúor-fenil)-3-(8-hidroxiquino-
lin-5-il)-7-fenil-5H-tiazol[3,2-a]pirimidina-6-carbo-
nitrilo 4 se conseguía mediante una síntesis de tres 
componentes en un solo reactor usando p-TSA (10 
mol %) en el reflujo del CH3CN. El compuesto 4 se uti-
lizaba para sintetizar una nueva serie de triazol[3,2-a]
pirimidinas 6-8, [1,2,4]triazol[3,4-b][1,3,4]tiadiazoles 
10, 11a-c y 12a-c. Es decir, se obtenían derivados de 
las bases de Schiff 13a-c del compuesto 9 mediante 
el tratamiento con algunos aldehídos aromáticos. Es-
tos últimos compuestos se sometían a una reacción 
de  Mannich con morfolina para dar los derivados N-
morfolinometil-amino 14a-c. Las estructuras de los 
nuevos compuestos son respaldadas por las técnicas 
de FT IR, 1H NMR, 13CNMR, espectroscopia de ma-
sas y análisis elemental. Todos los compuestos recién 
sintetizados eran sometidos a un screening para su 
actividad antimicrobiana.
Palabras clave: Reacción en un único reactor; tria-
zol [3,2-a] pirimidinas; triazoles; triazol [3,4-b] tiadia-
zoles; actividad antimicrobiana
RESUM
La síntesi del 5-(4-flúor-fenil)-3-(8-hidroxiquinolin-
5-il)-7-fenil-5H-tiazol[3,2-a]pirimidina-6-carbonitrilo 
4  s’aconseguia per mitjà d’una síntesi de tres compo-
nents en un únic reactor fent servir p-TSA (10 mol %) 
en el reflux del CH3CN. El compost 4 s’utilitzava per 
sintetitzar una nova sèrie de triazol[3,2-a]pirimidinas 
6-8, [1,2,4]triazol[3,4-b][1,3,4]tiadiazoles 10, 11a-c y 
12a-c. Es a dir, s’obtenien derivats de les bases de Schi-
ff 13a-c del compost 9 per mitjà d’un tractament amb 
alguns derivats aromàtics. Aquests últims compostos 
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es sotmetien a una reacció de  Mannich amb morfolina 
per donar els derivats N-morfolinometil-amino 14a-c. 
Les estructures dels nou compostos es troben recol-
zades per les tècniques de FT IR, 1H NMR, 13CNMR, 
espectroscòpia de masses i anàlisis elemental. Tots els 
compostos acabats de sintetitzar es sotmetien a un 
screening per la seva activitat antimicrobiana.
Paraules clau: Reacció en un únic reactor; triazol 
[3,2-a] pirimidinas; triazoles; triazol[3,4-b]tiadiazo-
les; activitat antimicrobiana
INTRODUCTION
In recent years, increasing interest has been focused 
on synthesis of thiazolopyrimidines due to  their  abili-
ty  to  inhibit  2-methylerythritol-2,4-cyclodiphosphate 
synthase. 1 They have been also used as analgesic, anti-
parkinsonian agents, 2 anticancer agents, 3-5 phosphate 
inhibitors 6 and acetylcholinesterase inhibitors.7 Vari-
ous condensed thiazolopyrimidines have been report-
ed as antimicrobial substances, 8-10 anti-inflammatory 11 
and antiviral activity and as inhibitors of HIV-1 reverse 
transcriptase.12  A variety of synthetic methods have 
been reported for preparation of thiazolopyrimidine 
derivatives. One of the commonest methods involves 
cyclization of dihydropyrimidinethiones with 1,2-di-
electrophiles such as 2-bromoketones, 13 chloroacetyl 
chloride,14 chloroacetic acid, 11, 12, 15 methyl chloroace-
tate 16 and N-aryl-2-chloroacetamides.17 Most of these 
methods involve two steps: Biginelli reaction as well 
as cyclization. To the best of our knowledge, there is 
no direct route for construction of the thiazolopyrim-
idine scaffold in a one-pot procedure. Nowadays, mul-
ticomponent domino reactions (MDRs), particularly 
those performed in aqueous media, have become an 
increasingly useful tool for the synthesis of chemical-
ly and biologically important compounds because of 
their convergence, atom economy, and other suitable 
characteristics from the point of view of green chem-
istry. 18–22 With  all   the  above  facts  in  mind  and  as 
a  part  of  our program  directed towards  the  syn-
thesis of  heterocycles derived from 5-(2-aminothi-
azol-4-yl)-8-hydroxyquinoline of potential biological 
interest, 10, 23 we aimed to report herein the one-pot 
three component synthesis of  5-(4-fluoro-phenyl)-3-
(8-hydroxyquinolin-5-yl)-7-phenyl-5H-thiazolo[3,2-a]
pyrimidine-6-carbonitrile 4  as  a conveniently accessi-
ble   precursor   for   the   synthesis   of  thiazolo[3,2-a] 
pyrimidines and other related 1,2,4-triazoles  and tri-
azolo[3,4-b][1,3,4]thiadiazol systems. 
RESULTS AND DISCUSSION
Chemistry
In this paper and as a consequence of our previous 
work on the green synthesis of  heterocyclic 
compounds of biological interest, 24-26 we investigated 
a novel green and efficient protocol that was 
developed for the construction of pyrido[2,3-d][1,3]
thiazolo[3,2-a]pyrimidine moiety 4 via the one –pot 
three component condensation of 5-(2-aminothiazol-
4-yl)-8-hydroxyquinoline 1, 4-fluorobenzaldehyde 2 
and benzoylacetonitrile 3 using p-toluene sulphonic 
acid (10 mol%) in refluxing acetonitrile to give the two 
isomeric mixture of thiazolo[3,2-a]pyrimidines 4 and 
5  as shown in Scheme 1.  In our initial study, we tried 
to optimize the model procedure mentioned above by 
detecting the efficiency of different solvent conditions, 
H2O, EtOH, MeOH, DCM, CHCl3, THF and CH3CN 
as well as, catalyst amount. In each case, the reactants 
(10 mmol) were allowed together in 10 mL solvent at 
reflux temperature and in the presence of different 
amount of p-TSA. It was found that CH3CN was the 
most suitable solvent for this transformation among 
others, which afforded the yields of 29-53%. After 
extensive screening of the mole ratio (5, 10, 15, 20 mol 
%) of p-TSA, we found that 10 mol % was suitable for 
maximum conversion of product (79% yield) and it was 
clear that the increase in the mole ratio did not improve 
neither the yield nor the reaction time (Scheme 1). 
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Scheme 1. Synthetic pathways for the formation of 4 and 5
The formation of compounds 4 as a major rather 
than the isomeric 5 was confirmed by the 1H-NMR 
and 13 C-NMR spectra. The chemical shift for the 
pyrimidine CH-5 and CH-7 for both compounds 
is markedly affected by the nature of the adjacent 
nitrogen. 24, 27,28 The 1 HNMR spectral data of compound 
4 showed that δ-values at 4.4 ppm attributed to 
the pyrimidine CH-5 that near to the sp3 nitrogen 
(pyrrole type), differs from δ-values of the pyrimidine 
CH-7 in compounds 5 that adjacent to sp2 nitrogen 
(pyridine type) which appeared at 3.5 ppm. Also, the 
preference for structures 4 over 5 was shown by 13 
CNMR spectra. Thus, the 13C-NMR (DMSO-d6) of 4, 
showed a singlet at δ 45.5 ppm that correspond to the 
pyrimidine CH-5 (pyrrole type). Whereas, 13C-NMR 
(DMSO-d6) of 5 displayed a singlet at δ 62.9 ppm, due 
to the pyrimidine CH-7 (pyridine type), respectively. 
The plausible mechanism for the formation of 4 was 
depicted in scheme 2.
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Scheme 2. One –pot three component mechanistic 
pathway for the formation of 4
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A further confirmation of structure 4 could be 
obtained by the alkaline hydrolysis  of the cyano group 
in compound 4 to yield the corresponding 5-(4-fluoro 
phenyl_-3-(8-hydroxyquniolin-5-yl)-7-phenyl-5H-
thiazolo[3,2-a]pyrimidin-6-carboxylic acid 6. IR spectra 
of 6 showed the absence of absorption band at 2220 
cm-1 for CN function in compound 4 and gave a broad 
band at 3020-2790 and 1710 cm-1 attributed to OH and 
C=O of carboxylic group, respectively. Esterification of 
compound 6 with absolute ethanol in presence of conc 
H2SO4, afforded the corresponding 6-ethyl carboxylate 
derivative 7. IR spectrum of compound 7, showed an 
absorption band at 1747 cm-1 due to C=O ester group. 
Hydrazonolysis of 7 by treatment with hydrazine 
hydrate gave the acid hydrazide derivative 8. In the IR 
spectrum of 8, N-H function was observed at 3336-3257 
cm-1, which was absent in precursor 7. In the 1H NMR 
spectrum, the characteristic proton of the CONH group 
was observed at δ 9.25 ppm as a singlet. The reaction 
of 8 with carbon disulphide and potassium hydroxide 
followed by the treatment with hydrazine hydrate, 
furnished 4-amino-5-[5-(4-fluorophenyl)-7-phenyl-
3-(8-hydroxyquinolin-5-yl)-5H-[1,3]thiazolo[3,2-a]
pyrimidin-6-yl]-4H-1,2,-triazole-3-thiol 9. Alternatively, 
the triazole 9 could not be synthesized via the fusion of 
6 with thiocarbohydrazide due to its high melting point 
(233 °C) in which the thiocarbohydrazide undergoes 
decomposition (169-174 °C). The IR spectra of compound 
9 showed absorption bands at 3360, 3270, 3160 and 1210 
cm-1 attributed to NH2, NH and C=S groups, respectively. 
Its 1 HNMR spectra displayed two characteristic 
singlets at 11.3 and 5.85 ppm corresponding to NH 
and NH2, respectively (Scheme 3). The amino and 
mercapto groups are ready-made nucleophilic centers 
for the synthesis of condensed heterocyclic rings. 
Thus, the ring closure of s-triazole 9 with carbon 
disulphide in methanolic potassium hydroxide formed 
5-[5-(4-fluorophenyl)-6-(6-mercapto-[1,2,4]triazolo[3,4-
b]-3-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimidin-3-yl]-
quinoline-8-ol 10, which when treated with methyl 
iodide, ethyl iodide and benzyl bromide afforded the 
s-alkylating products 11a-c,  in good yields. A one-step 
preparation of 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles 
12a-c, from the corresponding 4-aminotriazole 9 and 
carboxylic acids by prolonged heating with phosphoryl 
chloride was achieved.
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Scheme 3. Synthetic pathways for the formation of 6-9
It is worthy to note that compound 12a (R = CH3) 
could be obtained, in a rather better yield: (88 %), 
directly by the reaction of 9 with acetic anhydride. 
The IR spectrum of 12a showed no NH bands and 
the 1H NMR spectrum showed a singlet at 2.66 ppm 
corresponding to the methyl substituent at position 
6 (Scheme 4). The desired triazole Schiff bases 
13a-c, were prepared by heating compound 9 and 
appropriate aldehydes in glacial acetic acid. The 1H 
NMR spectrum of 13a-c, displayed the characteristic 
peaks at 9.3-9.45 and 10.96-11.20 ppm attributed to 
the imine and triazole NH protons. Mass spectrum 
of compound 13b as an example showed a peak 
analogous to the molecular ion at m/z 688.17 (M+, 
62%). Mannich base formation can take place at 
the triazole NH protons in compounds 13a-c by 
condensing with formaldehyde and morpholine to give 
the corresponding N-morpholinomethyl products 
14a-c. The 1H-NMR spectra of compounds 14a-c 
showed the absence of triazole NH proton signals 
and displayed characteristic >N-CH2-N< signals at 
around δ 4.48-4.52 ppm , beside to broad singlets at 
2.50-2.58 and 3.30-3.38 ppm due to the N(CH2)2 and 
O(CH2)2 of the morpholine moiety, reinforced the 
formation of compounds 14a-c (Scheme 4). 
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PHARMACOLOGICAL STUDIES
Antimicrobial Activity
In vitro antimicrobial activity was carried out by 
using the agar well-diffusion method. 29 All of the newly 
synthesized compounds 4-14a-c was initially evaluated 
for their antibacterial activity against Staphylococcus 
aureus (AUMC B.54), Bacillus cereus (AUMC B.52) as 
a Gram positive bacteria and Escherichia coil (AUMC 
B.53), and Pseudomonas aeruginosa (AUMC B. 73) 
as Gram negative bacteria using chloramphenicol as 
control. The antifungal activity was investigated against 
Candida albicans (AUMC No. 418) and Aspergillus 
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flavus (AUMC No. 1276) using Clotrimazole as 
control. The results were recorded for each tested 
compound as the mean diameter of inhibition zone 
of bacteria or fungal growth around the discs in mm 
in Table 1. It was observed that compounds 9, 10, 
12b and 14c exhibited the highest activity against 
S.aureus and E. coli. Compound 11b displayed 
an equipotent to chloramphenicol in inhibiting 
the growth of S.aureus and B cereus. Whereas, 
Compound 13b showed a remarkable activity against 
B. cereus and P. aeruginosa. On the other hand, 
compound 14c gave the highest antifungal activity 
against both of tested fungi species C.albicans and A 
flavus. While, compounds 11c and 13b were almost 
equipotent to clotrimazole in inhibiting the growth 
of C.albicans only. Other compounds exhibited weak 
activity against C. albicans and A flavus as compared 
to standard Clotrimazole (Table 1).
Table 1. Antimicrobial activity of the newly thiazolo[3,2-a]
pyrimidines
ART. 4351
Table 1. Antimicrobial activity of the newly thiazolo[3,2-a]pyrimidines
Compound                                                        Mean zone inhibition (in mm)a,b
No.                                      ___________________________________________________________
                                  Gram (+) bacteria                 Gram (-) bacteria                 Fungi
                                 _________________        ______________          ____________________
                                  S.aureus        B. cereus  E.coli   P. aeruginosa     C.albicans     A flavus
4 11 10 10 - 13 -
6
7
8
8
10
14         
15
-
-
13
13
-
9
-
19
-
-
-                 
-
-
-
9 31 - 29 19 12 10
10 33 18 26 12 7 18
11a 14 - - - - -
11b 28 26 - - 18 -
11c 15 16 17 12 26 18
12a - - - - 8 -
12b 36 20 28 - - 17
12c 15 11 - - - -
13a 6 - 16 33 10 11
13b - 30 - 33 25 -
13c 13 17 9 13 - -
14a - 15 14 - - -
14b 18 - - - 9 13
14c 29 25 25 - 34 44
Chlorampenicol 28 26 20 32 - -
Clotrimazole   - - - 26 40
           a Values are mean (n= 3)
         b All the test and the standard drug were tested at the concentration of 20 mg/ml
        ‘–’ indicates no sensitivity or mean inhibition zone diameter lower than 7 mm
 a Values are mean (n= 3)
b All the test and the standard drug were tested at the   
 concentration of 20 mg/ml
‘–’ indicates no sensitivity or mean inhibition zone diam 
 eter lower than 7 mm
CONCLUSION
It is concluded that the present work provides a 
convenient and efficient route for the preparation of 
new thiazolo [3,2-a] pyrimidines, 4, 6, 7 and 8 and 
their derived N-aminotriazole thiols 9, Schiff bases 
13a-c, Mannich products 14a-c and triazolo[3,4-b]
thiadiazoles, 10, 11a-c and 12a-c. All of the newly 
synthesized compounds have been screened for their 
antimicrobial activities. Compounds 9, 10, 12b and 
14c exhibited the highest activity against S.aureus 
and E. coli. Compound 13b showed a remarkable 
activity against B. cereus and P. aeruginosa. Com-
pounds 11c and 13b exihibited an equipotent activity 
against C.albicans only. Other compounds exhibited 
no or weak activity against the tested microorgan-
isms. This results may serve as a ready reference for 
the researchers to take advantage of proficient proce-
dure applied for the synthesis of novel series of deriv-
atives and further plausible  modifications which will 
augment the therapeutic potential of thiazolo [3,2-a] 
pyrimidine derivatives.
EXPERIMENTAL 
Melting points are uncorrected and determined us-
ing a Gallenkamp melting point apparatus. IR spec-
tra were recorded on a Pye-Unicam SP 3-100 spec-
trophotometer using the KBr Wafer technique. 1H 
NMR spectra were recorded on a Varian EM-390 90 
MHz spectrometer and on GNM-LA (400 MHz) in 
DMSO-d6 as a solvent and TMS as internal standard. 
Chemical shifts are expressed in ppm. 13C NMR spec-
tra were measured on a Varian EM-200, 100 MHz 
spectrometer. Mass spectra were determined on a 
JEOL JMS-600 spectrometer. Elemental analyses 
were carried out in the Microanalytical Unit at the at 
Assiut University (Egypt). Compound 1 was synthe-
sized using reported procedure. 23
General procedure for the Synthesis of 
3-(8-hydroxyquinolin-5-yl)-thiazolo[3,2-a] 
pyrimidine-6-carbonitriles 4 and 5 A mixture 
of 5-(2-Aminothiazol-4-yl)-8-hydroxyquinoline 1 
(2.43 g, 10 mmol), 4-fluorobenzaldehyde 2 (1.24 g, 10 
mmol), benzoylacetonitrile 3 (1.45 g, 10 mmol), and 
PTSA (2.47 g, 20.00 mmol) was dissolved in acetoni-
trile (30 mL) and the resulting solution was refluxed 
for 3 h. After the completion of reaction the reaction 
mixture was cooled to room temperature and extract-
ed with CHCl3 (3 X 25 mL), washed successively with 
water (2 x 25 mL), 2% dilute HCl solution and dried 
over anhydrous Na2SO4. The residue was purified by 
preparative layer chromatography (PLC) [silica gel 
(F254) powder; petroleum ether–ethyl acetate (10:2)]. 
The solvent was removed under reduced pressure and 
the products were obtained. 
5-(4-Fluoro-phenyl)-3-(8-hydroxyqinolin-
5-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimidine-
6-carbonitrile (4). Orange solid, yield 79% (3.76 g), 
m.p. 208-210 °C. IR (KBr) : 2220 (CN), 1625 (C=N) 
cm-1.1H NMR (400 MHz, DMSO-d6): δ = 7.09- 8.60 
(m, 15 H, Ar-H), 6.55 (s, 1H, thiazole H-2), 4.40 (s, 
1H, pyrimidine H-5). 13C NMR (100 MHz, DM-
SO-d6): δ = 162.43, 161.57, 158.43 (d, JF-C = 243.2 Hz, 
CAr-F), 153.28, 150.77, 145.33, 142.46, 138.22, 135.01 
(2C), 133.25, 131.40, 129.58, 128.51 (2C), 126.43 (2C), 
125.71, 124.19, 122.24, 122.11, 116.27, 112.55 (2C), 
111.34, 95.07, 86.25, 45.40. MS: m/e 476.3 (M+, 23%). 
Anal. Calculated for C28H17FN4OS (476.52): C, 70.57; 
H, 3.60; N, 11.76; S, 6.73. Found: C, 70.75; H, 3.83; N, 
11.92; S 7.06.
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7-(4-Fluoro-phenyl)-3-(8-hydroxyqinolin-
5-yl)-5-phenyl-7H-thiazolo[3,2-a]pyrimi-
dine-6-carbonitrile (5). Orange solid, yield 12% 
(0.57 g), m.p. 268-270 °C. IR (KBr): 2225 (CN), 1630 
(C=N) cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 6.95- 
8.80 (m, 15 H, Ar-H), 6.58 (s, 1H, thiazole H-2), 3.50 
(s, 1H, pyrimidine H-7). 13C NMR (100 MHz, DM-
SO-d6): δ =163.46, 160.33, 158.51 (d, JF-C = 244.4 Hz, 
CAr-F), 153.29, 151.11, 148.17, 143.49, 139.34, 135.11 (2C), 
133.63, 130.29, 129.52, 128.77 (2C), 126.38 (2C), 125.92, 
123.60, 122.44, 121.16, 117.23, 112.81 (2C), 111.70, 
98.11, 88.13, 62.90. Anal. Calculated for C28H17FN4OS 
(476.52): C 70.57, H 3.60, N 11.76, S 6.73; found: C 70.85, 
H 3.49, N 11.43, S 7.11.
Synthesis of 5-(4-fluoro-phenyl)-3-(8-
hydroxyqinolin-5-yl)-7-phenyl-5H-thi-
azolo[3,2-a] pyrimidine-6-carboxylic acid (6)
A mixture of 4 (1.425 g, 3 mmol) and aqueous sodium 
hydroxide (15 mL 10%) in ethanol (20 mL) was heat-
ed under reflux for 3 h, then neutralized with diluted 
HCl. The solid precipitate that formed was filtered off, 
washed with water and crystallized from dioxane to 
give 6 as pale yellow needles, yield 69% (1.02 g), m.p. 
233-235 °C. IR (KBr):  3020-2790 (br, OH), 1710 (C=O), 
1628 (C=N) cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 
6.90- 8.55 (m, 15 H, Ar-H), 6.65 (s, 1H, thiazole H-2), 
4.65 (s, 1H, pyrimidine H-5). Anal. Calculated for 
C28H18FN3O3S (495.52): C 67.87, H 3.66, N 8.48, S 6.47; 
Found: C 67.48, H 3.44, N 8.86, S 6.72.
Synthesis of ethyl-5-(4-fluoro-phenyl)-3-(8-
hydroxyqinolin-5-yl)-7-phenyl-5H-thiazolo 
[3,2-a]pyrimidine-6-carboxylate (7)
A mixture of 6 (2.47 g, 5 mmol) and H2SO4 (15 mL) 
in ethanol (40 mL) was heated under reflux for 5 h, 
then left to cool. The yellow crystals that formed were 
filtered off, washed with water and crystallized from 
ethanol to give  7 as yellow needles, yield 66% (1.73 
g), m.p. 195-197 °C. IR (KBr): 1747 (C=O), 1633 (C=N) 
cm-1, 1H NMR(400 MHz, DMSO-d6): δ = 6.99- 8.68 
(m, 15 H, Ar-H), 6.70 (s, 1H, thiazole H-2), 4.70 (s, 1H, 
pyrimidine H-5), 4.25 (q, J = 6.9 Hz, 2H, CH2),  1.35 
(t, J =7.8 Hz, 3H, CH3). Anal. Calculated for C30H22F-
N3O3S (523.58): C 68.82, H 4.24, N 8.03, S 6.12; Found: 
C 69.13, H 4.45, N 7.89, S 6.38.
Synthesis of 5-(4-fluoro-phenyl)-3-(8-hydro-
xyqinolin-5-yl)-7-phenyl-5H-thiazolo[3,2-a]
pyrimidine-6-carbohydrazide (8)
A mixture of 7 (1.57 g, 3 mmol) and hydrazine hy-
drate (7 mL, 80%) in ethanol (30 mL) was heated un-
der reflux for 1 h. The solid precipitate that formed 
was filtered off, washed with water and crystallized 
from ethanol to give 8 as yellow needles, yield 71% 
(1.08 g), m.p. 215-217 °C. IR(KBr): 3336, 3257 (NH, 
NH2), 1710 (C=O), 1621 (C=N) cm-1. 1H NMR (400 
MHz, DMSO-d6): δ = 9.25 (s, 1H, NH), 6.90- 8.55 (m, 
15 H, Ar-H), 6.69 (s, 1H, thiazole H-2), 4.77 (s, 1H, 
pyrimidine H-5), 4.28 (s, 2H, NH2). 13C NMR (100 
MHz, DMSO-d6): δ = 165.13, 161.41, 159.11 (d, JF-C = 
240.7 Hz, CAr-F), 157.91, 153.33, 150.32, 146.29, 143.88, 
138.36, 135.16 (2C), 132.93, 131.44, 129.00, 127.76 
(2C), 125.88 (2C), 125.04, 123.77, 121.91, 120.22, 
117.66, 114.62 (2C), 113.55, 101.19, 49.30.  Anal. Cal-
culated for C28H20FN5O2S (509.55): C 66.00, H 3.96, N 
13.74, S 6.29; Found: C 66.37, H 4.19, N 13.63, S 6.09.
Synthesis of 5-[6-(4-amino-5-mercapto-
4H-[1,2,4]triazol-3-yl)-5-(4-fluoro-phenyl)-
7-phenyl-5H-thiazolo[3,2-a]pyrimidin-3-yl]-
quinolin-8-ol (9)
A mixture of 8 (2.03 g, 4 mmol), potassium  hydrox-
ide (0.22 g, 4 mmol), carbon disulphide (8 mL)  and 
ethanol (25 mL) was heated under reflux until the 
evolution of H2S ceases. The reaction mixture was 
concentrated, dissolved in water and acidified with 
HCl. The resulting product is treated with hydrazine 
hydrate (20 mL) in ethanol under reflux condition for 
7-8 hrs. After completion of reaction, the contents 
were poured into ice cold water which on neutraliza-
tion by glacial acetic acid. The resulting product was 
filtered, dried and crystallized from ethanol to give 9 
as orange crystals, yield 66% (1.50 g), m.p. 320-322 °C. 
IR (KBr): 3360, 3270, 3160 (NH, NH2), 1621 (C=N), 
1210 (C=S) cm-1. 1H NMR (90 MHz, DMSO-d6): δ = 
11.30 (s, 1H, NH), 6.85- 8.67 (m, 15 H, Ar-H), 6.65 
(s, 1H, thiazole H-2), 5.70 (s, 2H, NH2), 4.60 (s, 1H, 
pyrimidine H-5). 13C NMR (100 MHz, DMSO-d6): δ = 
163.12, 160.09, 158.17 (d, JF-C = 240.4 Hz, CAr-F), 153.49, 
150.30, 146.40 (2C), 139.81, 137.63, 135.05, 134.72, 
132.66, 130.15 (2C), 129.11 (2C), 128.22, 127.54, 
126.98, 126.33, 125.65 (2C), 123.71, 121.90, 115.33 
(2C), 111.54, 84.90, 48.60. MS: m/e 565.65 (M+, 47%). 
Anal. Calculated for C29H20FN7OS2 (565.64): C 61.58, 
H 3.56, N 17.33, S 11.34; Found: C 61.88, H 3.42, N 
17.09, S 1.69.
Synthesis of 5-[5-(4-fluorophenyl)-6-(6-mer-
capto-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-
3-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimidin-3-yl] 
-quinolin-8-ol (10)
To a solution of 9 (2.82 g, 4 mmol) in methanol (40 
mL), KOH (2.5 g) and CS2 (8 mL) were added and the 
reaction mixture was refluxed for 2 h. The solvent 
was removed under reduced pressure, and then the 
residue was poured into an ice-water mixture with 
stirring. The solid product obtained was washed with 
water, filtered and recrystallized from ethanol to give 
10 as yellow crystals, yield 80% (1.90 g), m.p. 177-179 
°C. IR (KBr): 3190 (NH), 1631 (C=N), 1217 (C=S) cm-1. 
1H NMR (90 MHz, DMSO-d6): δ = 11.25 (s, 1H, NH), 
6.88- 8.77 (m, 15 H, Ar-H), 
6.68 (s, 1H, thiazole H-2), 4.55 (s, 1H, pyrimidine 
H-5). MS: m/e 606.21 (M+, 63%). Anal. Calculated for 
C30H18FN7OS3 (607.70): C 59.29, H 2.99, N 16.13, S 
15.83; Found: C 59.64, H 2.83, N 15.88, S 16.08.
General procedure for the synthesis of 
5-[5-(4-Fluorophenyl)-6-(6-substitued thio-
[1,2,4]triazolo[3,4-b][1,3,4]thiadzol-3-yl)-
7phenyl-5H-thiazolo[3,2-a]pyrimidin-3-yl]-
quinolin-8-ol (11a-c)
A mixture of 10 (1.82 g, 3 mmol), methyl iodide, 
ethyl iodide  and/or benzyl bromide (3 mmol) in etha-
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nol (50 mL) was refluxed in the presence of anhydrous 
sodium acetate (1.5 g) for 4 h. The solid product sep-
arated from the hot mixture was filtered off, washed 
with water and recrystallized from dioxane.
5-[5-(4-Fluorophenyl)-6-(6-methyltio-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-7-phnyl-
5H-thiazolo[3,2-a]pyrimidin-3-yl]-quinolin-
8-ol (11a). Yellow crystals, yield 73% (1.36 g), m.p. 
146-148°C. IR (KBr): 2980 (CH-aliphatic), 1627(C=N), 
1170 (C-S) cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 
6.85- 8.69 (m, 15 H, Ar-H), 6.70 (s, 1H, thiazole H-2), 
5.11 (s, 1H, pyrimidine H-5), 2.55 (s, 3H, CH3). %). 13C 
NMR (100 MHz, DMSO-d6): δ =161.44, 155.37 (d, JF-C 
= 244.6 Hz, CAr-F), 151.36, 149.22, 144.87 (2C), 138.55, 
136.69, 135.18, 134.66, 132.19, 131.85 (2C), 130.14 (2C), 
128.87, 128.00, 127.11, 126.13, 125.66 (2C), 122.91, 
120.24, 114.79 (2C), 113.49 (2C), 110.45, 88.76, 51.93, 
19.66.  Anal. Calculated for C31H20FN7OS3 (621.73): C 
59.89, H 3.24, N 15.77, S 15.47; Found: C 60.25, H 3.37, 
N 15.39, S 15.08.
5-[5-(4-Fluorophenyl)-6-(6-ethylthio-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-7-phnyl-
5H-thiazolo[3,2-a]pyrimidin-3-yl]-quinolin-
8-ol (11b). Yellow crystals, yield 67% (1.3 g), m.p. 
116-118 °C. IR(KBr): 2995 (CH-aliphatic), 1622 (C=N), 
1163 (C-S) cm-1. 1H NMR (400 MHz, DMSO-d6): δ = 
7.09- 8.57 (m, 15 H, Ar-H), 6.55 (s, 1H, thiazole H-2), 
4.75 (s, 1H, pyrimidine H-5), 4.15 (q, J = 7.4 Hz, 2H, 
CH2), 1.27 (t, J = 7.4 Hz, 3H, CH3). Anal. Calculated 
for C32H22FN7OS3 (635.76): C 60.45, H 3.49, N 15.42, S 
15.13; Found: C 60.13, H 3.82, N 15.68, S 14.79.
5-[5-(4-Fluorophenyl)-6-(6-benzylth-
io-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-
7-phenyl-5H-thiazolo[3,2-a]pyrimidin-3-yl]-
quinolin-8-ol (11c). Yellow crystals, yield 61%, m.p. 
161-163 °C. IR (KBr): 2998 (CH-aliphatic), 1626 (C=N), 
1177 (C-S) cm-1. 1H NMR(400 MHz, DMSO-d6): δ = 
6.88- 8.80 (m, 15 H, Ar-H), 6.57 (s, 1H, thiazole H-2), 
4.60 (s, 1H, pyrimidine H-5), 4.20 (s, 2H, CH2). Anal. 
Calculated for C37H24FN7OS3 (697.83): C 63.68, H 3.47, 
N 14.05, S 13.78; Found: C 63.90, H 3.58, N 14.33, S 
13.44.
General procedure for the synthesis of 
5-[5-(4-Fluorophenyl)-6-(6-alkyl/aryl-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-7-phnyl-
5H-thiazolo[3,2-a]pyrimidin-3-yl]-quinolin-
8-ol (12a-c)
Method A: A mixture of 9 (1.13 g, 3 mmol) 
and aliphatic and/ or aromatic acids (3 mmol) in 
phosphoryl chloride (10 mL) was heated under reflux 
for 5 h. After cooling, the solvent was removed under 
reduced pressure and an ice-water mixture was added 
to the residue with stirring. The reaction mixture was 
neutralized with ammonium hydroxide and the solid 
precipitate formed was filtered and recrystallized 
from ethanol to give 12a-c.
Method B: A mixture of 9 (0.56 g, 1 mmol) and 
acetic anhydride (10 mL) was heated under reflux for 
2 h. After cooling, an ice-water mixture was added 
to the residue with stirring and the solid precipitate 
formed was filtered and recrystallized from ethanol 
to give 12a. Yield 88% (0.49 g), m.p. and mixed m.p. 
with a sample obtained by the above procedure are 
identical.
5-[5-(4-Fluorophenyl)-6-(6-methyl-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-7-phe-
nyl-5H-thiazolo[3,2-a]pyrimidin-3-yl]-quino-
lin-8-ol (12a). Yellow crystals, yield 73% 044 g), m.p. 
211-213 °C. IR (KBr): 2880 (CH-aliphatic), 1633 (C=N) 
cm-1. 1H NMR (90 MHz, DMSO-d6): δ = 6.89- 8.77 
(m, 15 H, Ar-H), 6.69 (s, 1H, thiazole H-2), 4.67 (s, 1H, 
pyrimidine H-5), 2.35 (s, 3H, CH3). Anal. Calculated 
for C31H20FN7OS2( 589.67): C 63.14, H 3.42, N 16.63, S 
10.88; Found: C 63.45, H 3.73, N 16.41, S 10.59.
5-[5-(4-Fluorophenyl)-6-(6-phenyl-[1,2,4]
triazolo[3,4-b][1,3,4]thiadiazol-3-yl)-7-phe-
nyl-5H-thiazolo[3,2-a]pyrimidin-3-yl]-quin-
olin-8-ol (12b).Yellow crystals, yield 57% (0.32 g), 
m.p. 271-273 °C. IR (KBr): 3010 (CH-aromatic, 2890 
(CH-aliphatic), 1630 (C=N) cm-1. 1H NMR(90 MHz, 
DMSO-d6): δ = 6.95- 8.80 (m, 20 H, Ar-H), 6.55 (s, 1H, 
thiazole H-2), 4.58 (s, 1H, pyrimidine H-5). Anal. Cal-
culated for C36H22FN7OS2 (651.73): C 66.34, H 3.40, N 
15.04, S 9.84; Found: C 66.72, H 3.70, N 15.36, S 9.62.
5-[5-(4-Fluorophenyl)-6-(6-(4-nitrophe-
nyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-
yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimidin-3-
yl]-quinolin-8-ol (12c).Yellow crystals, yield 65% 
(0.36 g), m.p. 305-307 °C. IR (KBr): 3055 (CH-aromat-
ic, 2895 (CH-aliphatic), 1629 (C=N) cm-1  1H NMR(400 
MHz, DMSO-d6): δ = 6.99- 8.87 (m, 19 H, Ar-H), 6.62 
(s, 1H, thiazole H-2), 4.50 (s, 1H, pyrimidine H-5). 
Anal. Calculated for C36H21FN8O3S2 (696.73): C 62.06, 
H 3.04, N 16.08, S 9.20; Found: C 62.39, H 2.79, N 
16.76, S 9.55.
General procedure for the synthesis of 
5-[6-[4-(substituted benzylidene ami-
no)-5-mercapto-4H-(1,2,4) triazole-3-yl]-5-
(4-fluoro-phenyl)-7-phenyl-5H-thiazolo[3,2-
a]-pyrimidin-3-yl]-quinolin-8-ol (13a-c)
Equimolar amounts of 9 and appropriate aromatic 
aldehydes (2 mmol ) in glacial acetic acid (5 mL) were 
heated under reflux for 2 h. The mixture was then 
cooled to room temperature, filtered and washed with 
water. The obtained solids were recrystallized from 
ethanol to afford the Schiff bases 13a-c.
5-[6-[4-(Benzylidene-amino)-5-mercap-
to-4H-(1,2,4)triazole-3-yl]-5-(4-fluoro-phe-
nyl)-7-phenyl-5H-thiazolo[3,2-a]pyrimidin-3-
yl]-quinolin-8-ol (13a). Yellow crystals, yield 66% 
(0.86 g), m.p. 229-231°C. IR (KBr): 3390 (NH), 3020 
(CH-aromatic), 1631 (C=N) cm-1. 1H NMR (90 MHz, 
DMSO-d6): δ = 10.96 (s, 1H, NH), 9.30 (s, 1H, N=CH), 
6.95- 8.80 (m, 20 H, Ar-H), 6.67 (s, 1H, thiazole H-2), 
4.49 (s, 1H, pyrimidine H-5).  Anal. Calculated for 
C36H24FN7OS2 (653.75): C 66.14, H 3.70, N 15.00, S 
9.81; Found: C 65.77, H 3.96, N 15.39, S 10.02.
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5-[6-[4-(4-Chlorobenzylidene-ami-
no)-5-mercapto-4H-(1,2,4)triazole-3-yl]-
5-(4-fluoro-phenyl)-7-phenyl-5H-thi-
azolo[3,2-a]pyrimidin-3-yl]-quinolin-8-ol 
(13b). Yellow crystals, yield 71% (0.96 g), m.p. 154-
156°C. IR (KBr): 3377 (NH), 3010 (CH-aromatic), 1623 
(C=N) cm-1. 1H NMR (90 MHz, DMSO-d6): δ = 11.15 
(s, 1H, NH), 9.38 (s, 1H, N=CH), 6.97- 8.86 (m, 19 H, 
Ar-H), 6.60 (s, 1H, thiazole H-2), 4.53 (s, 1H, pyrimi-
dine H-5). MS: m/e 688.17.65 (M+, 62%). Anal. Calcu-
lated for C36H23ClFN7OS2 (688.20): C 62.83, H 3.37, Cl 
5.15, N 14.25, S 9.32; Found: C 63.08, H 3.52, Cl 4.91, 
N 14.58, S 8.96.
5-[6-[4-(4-Methoxybenzylidene-amno) 
-5-mercapto-4H-(1,2,4)triazole-3-yl]-5-(4-
fluoro-phenyl)-7-phenyl-5H-thiazolo[3,2-a]
pyrimidin-3-yl]-quinolin-8-ol (13c).
Yellow crystals, yield 59% (0.8 g), m.p. 261-263°C. IR 
(KBr): 3325 (NH), 3018 (CH-aromatic), 1635 (C=N), 
1210 (C-O) cm-1.  1H NMR (90 MHz, DMSO-d6): δ = 
11.20 (s, 1H, NH), 9.45 (s, 1H, N=CH), 6.79- 8.90 (m, 
19 H, Ar-H), 6.54 (s, 1H, thiazole H-2), 4.60 (s, 1H, 
pyrimidine H-5), 3.35 (s, 3H, CH3). Anal. Calculated 
for C37H26FN7O2S2 (683.78): C 64.99, H 3.83, N 14.34, 
S 9.38; Found: C 64.63, H 4.09, N 14.13, S 9.77.
General procedure for the synthesis of 
4-(substituted benzylidene-amino)-5-[5-
(4-fluoro-phenyl)—3-(8-hydroxyquniolin-
5-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimi-
din-6-yl]-2-morpholin-4yl-methyl-[1,2,4]
triazole-3-thione (14a-c)
Formalin 40% (1 mL ) was added to a stirred solu-
tion of 13a-c (5 mmol) in absolute ethanol (40 mL). 
An ethanolic solution (10 mL) of morpholin  (5 mmol) 
was added portionwise to the reaction mixture, stirred 
for 3 h at room temperature, and left overnight in a re-
frigerator. The precipitate formed was filtered, washed 
with cold ethanol, dried, and crystallized from etha-
nol to afford compounds 14a-c.
4-(Benzylidene-amino)-5-[5-(4-fluoro-phe-
nyl)-3-(8-hydroxyquniolin-5-yl)-7-Phenyl--
5H-thiazolo[3,2-a]pyrimidin-6-yl]-2-morpho-
lin-4ylmethyl-[1,2,4]triazole-3-thione (14a). 
Yellow crystals, yield 73% (2.37 g), m.p. 187-189°C. IR 
(KBr): 2990, 2885 (CH-aliphatic), 1618 (C=N), 1377 
(C=S) cm-1. 1H NMR(400 MHz, DMSO-d6): δ = 9.30 
(s, 1H, N=CH), 6.81- 8.99 (m, 20 H, Ar-H), 6.69 (s, 
1H, thiazole H-2), 4.65 (s, 1H, pyrimidine H-5), 4.48 
(s, 2H, N-CH2-N), 3.30 (brs, 4H, 2CH2-O), 2.50 (brs, 
4H, 2CH2-N). Anal. Calculated for C41H33FN8O2S2 
(752.88): C 65.41, H 4.42, N 14.88, S 8.52; Found: C 
65.80, H 4.73, N 15.23, S 8.26.
4-(4-Chlorobenzylidene-amino)-5-[5-(4-
fluoro-phenyl)—3-(8-hydroxyquniolin-
5-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimi-
din-6-yl]-2-morpholin-4ylmethyl-[1,2,4]
triazole-3-thione (14b). Yellow crystals, yield 59% 
(2.0 g), m.p. 199-201°C. IR (KBr): 2989, 2890 (CH-al-
iphatic), 1622 (C=N), 1371 (C=S) cm-1. 1H NMR (90 
MHz, DMSO-d6): δ = 9.55 (s, 1H, N=CH), 6.90- 8.99 
(m, 19 H, Ar-H), 6.55 (s, 1H, thiazole H-2), 4.72 (s, 1H, 
pyrimidine H-5), 4.50 (s, 2H, N-CH2-N), 3.35 (brs, 
4H, 2CH2-O), 2.58 (brs, 4H, 2CH2-N). 13C NMR (100 
MHz, DMSO-d6): δ = 
162.03 (d, JF-C = 240.9 Hz, CAr-F), 154.44, 150.67, 
146.25, 141.35 (2C), 138.29, 137.11, 135.63, 133.26, 
132.77 (2C), 131.81 (2C), 129.06, 128.19, 127.45, 126.22 
(2C), 123.15, 119.55, 113.39 (2C), 111.12, 91.34, 78.66, 
73.19 (2C), 55.11 (2C), 51.93, 46.32. Anal. Calculated 
for C41H32ClFN8O2S2 (787.33): C 62.55, H 4.10, Cl 4.50, 
N 14.23, S 8.15; Found: C 62.88, H 4.44, Cl 4.21, N 
14.42, S 8.54.
4-(4-Methoxybenzylidene-amino)-5-[5-
(4-fluoro-phenyl)—3-(8-hydroxyquniolin-
5-yl)-7-phenyl-5H-thiazolo[3,2-a]pyrimi-
din-6-yl]-2-morpholin-4ylmethyl-[1,2,4]
triazole-3-thione (14c). Yellow crystals, yield 66% 
(2.24 g), m.p. 233-235°C. IR (KBr): 2985, 2895 (CH-al-
iphatic), 1628 (C=N), 1369 (C=S), 1215 (C-O) cm-1. 1H 
NMR(90 MHz, DMSO-d6): δ =  9.45 (s, 1H, N=CH), 
6.95- 9.02 (m, 19 H, Ar-H), 6.58 (s, 1H, thiazole H-2), 
4.68 (s, 1H, pyrimidine H-5), 4.52 (s, 2H, N-CH2-N), 
3.54 (s, 3H, CH3), 3.38 (brs, 4H, 2CH2-O), 2.55 (brs, 
4H, 2CH2-N). Anal. Calculated for C42H35FN8O3S2 
(782.91): C 64.43, H 4.51, N 14.31, S 8.19; Found: C 
64.79, H 4.32, N 14.27, S 8.43.
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